|
Atherosclerosis Riskier for Postmenopausal Women Than Same-Aged Men
|
|
The standard treatment for atherosclerosis might not be enough to prevent cardiovascular events in postmenopausal women at high risk, according to a new study. Adding to the danger for women, the researchers found, is that they have higher rates of nonobstructive heart disease. The researchers suggest that different medication regimens might be needed to adequately prevent the events. Read more.
|
|
|
Oral Minoxidil Prescriptions Spiked Last Year After Media Coverage
|
|
|
It might have seemed that almost overnight, more patients were coming into U.S. pharmacies with scripts for oral minoxidil late last summer. A new study determined that was the case—or close to it. Find out how media coverage and social media sharing had a significant effect on the switch from topical to oral minoxidil for hair loss.
|
|
Which T2D Drug Class Prevents Cardiac Events Best?
|
|
|
The American Diabetes Association recommended that two drug classes be used to treat patients with type 2 diabetes (T2D) and comorbidities. A study of U.S. veterans without pre-existing heart disease found that glucagon-like peptide-1 receptor agonists worked best in preventing outcomes such as nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death. Sodium-glucose cotransporter 2 inhibitors were not found as effective. Read more.
|
|
|
New Pharmacist Recommendation Series Video
|
|
In the latest Pharmacist Recommendation Series video, U.S. Pharmacist Editor-in-Chief Robert Davidson discusses KONVOMEP with Clinical Pharmacist Tammie Lee Demler. In this installment, Dr. Demler explains how KONVOMEP may give patients, particularly people with difficulty swallowing pills or capsules, an option for treatment tailored to their needs. Click here to view video.
|
|
